Study on Pulmonary Lymphangioleiomyomatosis in Humans
This observational study aimed to understand the disease processes of pulmonary lymphangioleiomyomatosis (LAM) at the cellular and molecular levels using the Toshiba Aquilion One CT device. Although designed to define the clinical course and pathogenesis of LAM, no specific results or findings have been reported yet.
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
Why it matters
Understanding LAM at a molecular level could lead to the development of effective therapies, as there are currently no treatments available and the prognosis for affected individuals is poor.
What this does not prove
The study has no posted results, and planned enrolment details and endpoints are not findings of the study.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Observational
- Participants / samples
- Not reported
- Randomised
- No
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- No
- Research areas
- Not classified
Original sources
- Trial registrationStudy of the Disease Process of Lymphangioleiomyomatosis ↗
Supporting passages (8)
study designThis study is designed to determine the disease processes involved at the level of cells and molecules, in order to develop more effective therapy.
subjectsIndividuals with pulmonary lymphangioleiomyomatosis develop severe destructive lung disease.
randomizedThis study is designed to (a) define the clinical course of the disease and (b) elucidate the pathogenesis of the disease at the cellular and molecular levels, in order to develop more effective therapy.
regulatory approval"isFdaRegulatedDevice": false
interventionThe Toshiba Aquilion ONE CT system is currently being used for studies in both general CT radiology and CT cardiac imaging.
primary endpoint"description": "To define the molecular basis of the remarkable proliferation of immature appearing smooth muscle cells, which is the cause of many of the clinical manifestations, and perhaps thereby to improve our understanding of the mechanism of smooth muscle cell proliferation in other diseases, e.g., interstitial lung diseases, asthma, atherosclerosis, hypertension, and post-angioplastic coronary restenosis.
findingsCurrently, there is no effective therapy for the disease and the prognosis is poor.
limitationsNo results are posted. Planned enrolment and endpoints are not findings.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.